Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-10-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientregistrationglioblastomatumorcreatinine
  Phrases that lowered it: pressureand safetyefficacy andadministrationthe efficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 22 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 30.8% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.6% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma NCT01730950 · started 2012 · scored riskier than 90% of active trials completed
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors NCT01609790 · started 2012 · scored riskier than 67% of active trials completed
• Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme NCT01822275 · started 2013 · scored riskier than 97% of active trials terminated
• Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma NCT00884741 · started 2009 · scored riskier than 64% of active trials completed
• Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme NCT01062399 · started 2010 · scored riskier than 80% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.